Contribution of natural inhibitors to the understanding of the PI3K/PDK1/PKB pathway in the insulin-mediated intracellular signaling cascade

International Journal of Molecular Sciences

Volumn 9, Issue 11, 2008, Pages 2217-2230

  Jae, Youl Cho ^a   Park, Jongsun ^b  

^a Kangwon National University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

3 phosphoinositide dependent protein kinase 1; Diabetes mellitus; Natural inhibitors; Phosphatidylinositol 3 kinase; Protein kinase B

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GELDANAMYCIN; GLUCOSE; HERBIMYCIN; INSULIN; MACBECIN I; OKADAIC ACID; PHOSPHATIDYLINOSITOL 3 KINASE; PLECKSTRIN; PROTEIN KINASE B; RAPAMYCIN; WORTMANNIN;

ANTIINFLAMMATORY ACTIVITY; BINDING AFFINITY; CELL MEMBRANE; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME MECHANISM; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW;

EID: 56449116314     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms9112217     Document Type: Review

References (71)

1. Foster, D.W.; McGarry, J.D. The metabolic derangements and treatment of diabetic ketoacidosis. N. Engl. J. Med. 1983, 309, 159-169.
2. Coccheri, S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs 2007, 67, 997-1026.
3. Bretzel, R.G.; Eckhard, M.; Brendel, M.D. Pancreatic islet and stem cell transplantation: New strategies in cell therapy of diabetes mellitus. Panminerva Med. 2004, 46, 25-42.
4. Kahn, B.B. Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance. Cell 1998, 92, 593-596.
5. Saltiel, A.R.; Pessin, J.E. Insulin signaling pathways in time and space. Trends Cell. Biol. 2002, 12, 65-71.
6. Taylor, S.I. Deconstructing type 2 diabetes. Cell 1999, 97, 9-12.
7. Moller, D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001, 414, 821-827.
8. Kahan, B.D. Sirolimus-based immunosuppression: present state of the art. J. Nephrol. 2004, 17 Suppl 8, S32-39.
9. Thompson, E.J.; MacGowan, J.; Young, M.R.; Colburn, N.; Bowden, G.T. A dominant negative cjun specifically blocks okadaic acid-induced skin tumor promotion. Cancer Res. 2002, 62, 3044-3047.
10. Whitesell, L.; Mimnaugh, E.G.; De Costa, B.; Myers, C.E.; Neckers, L.M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8328.
11. Ui, M.; Okada, T.; Hazeki, K.; Hazeki, O. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. Trends Biochem. Sci. 1995, 20, 303-307.
12. Martinez, D.; Vermeulen, M.; Trevani, A.; Ceballos, A.; Sabatte, J.; Gamberale, R.; Alvarez, M.E.; Salamone, G.; Tanos, T.; Coso, O.A.; Geffner, J. Extracellular acidosis induces neutrophil activation by a mechanism dependent on activation of phosphatidylinositol 3-kinase/Akt and ERK pathways. J. Immunol. 2006, 176, 1163-1171.
13. Pandey, V.; Mihara, S.; Fensome-Green, A.; Bolsover, S.; Cockcroft, S. Monomeric IgE stimulates NFAT translocation into the nucleus, a rise in cytosol Ca2+, degranulation, and membrane ruffling in the cultured rat basophilic leukemia-2H3 mast cell line. J. Immunol. 2004, 172, 4048-4058.
14. Lee, J.Y.; Kim, J.Y.; Lee, Y.G.; Shin, W.C.; Chun, T.; Rhee, M.H.; Cho, J.Y. Hydroquinone, a reactive metabolite of benzene, reduces macrophage-mediated immune responses. Mol. Cells. 2007, 23, 198-206.
15. Falasca, M.; Maffucci, T. Role of class II phosphoinositide 3-kinase in cell signalling. Biochem. Soc. Trans. 2007, 35, 211-214.
16. Carnero, A.; Blanco-Aparicio, C.; Renner, O.; Link, W.; Leal, J.F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 2008, 8, 187-198.
17. Cifuentes, M.; Rojas, C.V. Antilipolytic effect of calcium-sensing receptor in human adipocytes. Mol. Cell. Biochem. 2008, 319, 17-21.
18. Li, H.B.; Ge, Y.K.; Zheng, X.X.; Zhang, L. Salidroside stimulated glucose uptake in skeletal muscle cells by activating AMP-activated protein kinase. Eur. J. Pharmacol. 2008, 588, 165-169.
19. Kanazawa, H.; Ohsawa, K.; Sasaki, Y.; Kohsaka, S.; Imai, Y. Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma - dependent pathway. J. Biol. Chem. 2002, 277, 20026-20032.
20. Shimaya, A.; Kovacina, K.S.; Roth, R.A. On the mechanism for neomycin reversal of wortmannin inhibition of insulin stimulation of glucose uptake. J. Biol. Chem. 2004, 279, 55277-55282.
21. Tang, X.; Wang, L.; Proud, C.G.; Downes, C.P. Muscarinic receptor-mediated activation of p70 S6 kinase 1 (S6K1) in 1321N1 astrocytoma cells: permissive role of phosphoinositide 3-kinase. Biochem. J. 2003, 374, 137-143.
22. Hinault, C.; Mothe-Satney, I.; Gautier, N.; Van Obberghen, E. Amino acids require glucose to enhance, through phosphoinositide-dependent protein kinase 1, the insulin-activated protein kinase B cascade in insulin-resistant rat adipocytes. Diabetologia 2006, 49, 1017-1026.
23. Jensen, J.; Brennesvik, E.O.; Lai, Y.C.; Shepherd, P.R. GSK-3beta regulation in skeletal muscles by adrenaline and insulin: evidence that PKA and PKB regulate different pools of GSK-3. Cell. Signal. 2007, 19, 204-210.
24. Hennersdorf, F.; Florian, S.; Jakob, A.; Baumgartner, K.; Sonneck, K.; Nordheim, A.; Biedermann, T.; Valent, P.; Buhring, H.J. Identification of CD13, CD107a, and CD164 as novel basophil-activation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res. 2005, 15, 325-335.
25. Arndt, P.G.; Suzuki, N.; Avdi, N.J.; Malcolm, K.C.; Worthen, G.S. Lipopolysaccharide-induced c-Jun NH2-terminal kinase activation in human neutrophils: role of phosphatidylinositol 3-Kinase and Syk-mediated pathways. J. Biol. Chem. 2004, 279, 10883-10891.
26. Okada, T.; Sakuma, L.; Fukui, Y.; Hazeki, O.; Ui, M. Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J. Biol. Chem. 1994, 269, 3563-3567.
27. Wymann, M.P.; Bulgarelli-Leva, G.; Zvelebil, M.J.; Pirola, L.; Vanhaesebroeck, B.; Waterfield, M.D.; Panayotou, G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell. Biol. 1996, 16, 1722-1733.
28. Meyers, R.; Cantley, L.C. Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase. J. Biol. Chem. 1997, 272, 4384-4390.
29. Woscholski, R.; Kodaki, T.; McKinnon, M.; Waterfield, M.D.; Parker, P.J. A comparison of demethoxyviridin and wortmannin as inhibitors of phosphatidylinositol 3-kinase. FEBS Lett. 1994, 342, 109-114.
30. Stack, J.H.; Emr, S.D. Vps34p required for yeast vacuolar protein sorting is a multiple specificity kinase that exhibits both protein kinase and phosphatidylinositol-specific PI 3-kinase activities. J. Biol. Chem. 1994, 269, 31552-31562.
31. Cutler, N.S.; Heitman, J.; Cardenas, M.E. STT4 is an essential phosphatidylinositol 4-kinase that is a target of wortmannin in Saccharomyces cerevisiae. J. Biol. Chem. 1997, 272, 27671-27677.
32. Brunn, G.J.; Williams, J.; Sabers, C.; Wiederrecht, G.; Lawrence, J.C., Jr.; Abraham, R.T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 1996, 15, 5256-5267.
33. Alarcon, C.M.; Heitman, J.; Cardenas, M.E. Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast. Mol. Biol. Cell. 1999, 10, 2531-2546.
34. Sarkaria, J.N.; Tibbetts, R.S.; Busby, E.C.; Kennedy, A.P.; Hill, D.E.; Abraham, R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res. 1998, 58, 4375-4382.
35. Hartley, K.O.; Gell, D.; Smith, G.C.; Zhang, H.; Divecha, N.; Connelly, M.A.; Admon, A.; Lees-Miller, S.P.; Anderson, C.W.; Jackson, S.P. DNA-dependent protein kinase catalytic subunit: A relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell 1995, 82, 849-856.
36. Stravopodis, D.J.; Margaritis, L.H.; Voutsinas, G.E. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr. Med. Chem. 2007, 14, 3122-3138.
37. Prodromou, C.; Pearl, L.H. Structure and functional relationships of Hsp90. Curr. Cancer Drug Targets 2003, 3, 301-323.
38. Roe, S.M.; Prodromou, C.; O'Brien, R.; Ladbury, J.E.; Piper, P.W.; Pearl, L.H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42, 260-266.
39. Sato, S.; Fujita, N.; Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. U S A. 2000, 97, 10832-10837.
40. Wei, Q.; Xia, Y. Roles of 3-phosphoinositide-dependent kinase 1 in the regulation of endothelial nitric-oxide synthase phosphorylation and function by heat shock protein 90. J. Biol. Chem. 2005, 280, 18081-18086.
41. Fontana, J.; Fulton, D.; Chen, Y.; Fairchild, T.A.; McCabe, T.J.; Fujita, N.; Tsuruo, T.; Sessa, W.C. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt-dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ. Res. 2002, 90, 866-873.
42. Yun, B.G.; Matts, R.L. Hsp90 functions to balance the phosphorylation state of Akt during C2C12 myoblast differentiation. Cell Signal. 2005, 17, 1477-1485.
43. Fujita, N.; Tsuruo, T. Survival-signaling pathway as a promising target for cancer chemotherapy. Cancer Chemother. Pharmacol. 2003, 52 Suppl 1, S24-28.
44. Supko, J.G.; Hickman, R.L.; Grever, M.R.; Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 1995, 36, 305-315.
45. Schnur, R.C.; Corman, M.L.; Gallaschun, R.J.; Cooper, B.A.; Dee, M.F.; Doty, J.L.; Muzzi, M.L.; Moyer, J.D.; DiOrio, C.I.; Barbacci, E.G.; et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J. Med. Chem. 1995, 38, 3806-3812.
46. Scheuer, P.J. Marine natural products. Diversity in molecular structure and bioactivity. Adv. Exp. Med. Biol. 1996, 391, 1-8.
47. Suganuma, M.; Fujiki, H.; Suguri, H.; Yoshizawa, S.; Hirota, M.; Nakayasu, M.; Ojika, M.; Wakamatsu, K.; Yamada, K.; Sugimura, T. Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter. Proc. Natl. Acad. Sci. USA 1988, 85, 1768-1771.
48. Rami, B.G.; Chin, L.S.; Lazio, B.E.; Singh, S.K. Okadaic-acid-induced apoptosis in malignant glioma cells. Neurosurg. Focus 2003, 14, e4.
49. Dounay, A.B.; Forsyth, C.J. Okadaic acid: the archetypal serine/threonine protein phosphatase inhibitor. Curr. Med. Chem. 2002, 9, 1939-1980.
50. McCluskey, A.; Sim, A.T.; Sakoff, J.A. Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. J. Med. Chem. 2002, 45, 1151-1175.
51. Matsuzawa, S.; Suzuki, T.; Suzuki, M.; Matsuda, A.; Kawamura, T.; Mizuno, Y.; Kikuchi, K. Thyrsiferyl 23-acetate is a novel specific inhibitor of protein phosphatase PP2A. FEBS Lett. 1994, 356, 272-274.
52. Li, Y.M.; Casida, J.E. Cantharidin-binding protein: identification as protein phosphatase 2A. Proc. Natl. Acad. Sci. USA 1992, 89, 11867-11870.
53. Bryant, N.J.; Govers, R.; James, D.E. Regulated transport of the glucose transporter GLUT4. Nat. Rev. Mol. Cell. Biol. 2002, 3, 267-277.
54. Dickey, R.W.; Bobzin, S.C.; Faulkner, D.J.; Bencsath, F.A.; Andrzejewski, D. Identification of okadaic acid from a Caribbean dinoflagellate, Prorocentrum concavum. Toxicon. 1990, 28, 371-377.
55. Dounay, A.B.; Urbanek, R.A.; Sabes, S.F.; Forsyth, C.J. Total Synthesis of the Marine Natural Product 7-Deoxy-okadaic Acid: A Potent Inhibitor of Serine/Threonine-Specific Protein Phosphatases. Angew. Chem. Int. Ed. Engl. 1999, 38, 2258-2262.
56. Dounay, A.B.; Urbanek, R.A.; Frydrychowski, V.A.; Forsyth, C.J. Expedient access to the okadaic acid architecture: a novel synthesis of the C1-C27 domain. J. Org. Chem. 2001, 66, 925-938.
57. Kita, A.; Matsunaga, S.; Takai, A.; Kataiwa, H.; Wakimoto, T.; Fusetani, N.; Isobe, M.; Miki, K. Crystal structure of the complex between calyculin A and the catalytic subunit of protein phosphatase 1. Structure. 2002, 10, 715-724.
58. Cardenas, M.E.; Cutler, N.S.; Lorenz, M.C.; Di Como, C.J.; Heitman, J. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 1999, 13, 3271-3279.
59. Sormani, R.; Yao, L.; Menand, B.; Ennar, N.; Lecampion, C.; Meyer, C.; Robaglia, C. Saccharomyces cerevisiae FKBP12 binds Arabidopsis thaliana TOR and its expression in plants leads to rapamycin susceptibility. BMC Plant Biol. 2007, 7, 26.
60. Krummrei, U.; Baulieu, E.E.; Chambraud, B. The FKBP-associated protein FAP48 is an antiproliferative molecule and a player in T cell activation that increases IL2 synthesis. Proc. Natl. Acad. Sci. USA 2003, 100, 2444-2449.
61. Crespo, J.L.; Hall, M.N. Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 2002, 66, 579-591, table of contents.
62. Helliwell, S.B.; Wagner, P.; Kunz, J.; Deuter-Reinhard, M.; Henriquez, R.; Hall, M.N. TOR1 and TOR2 are structurally and functionally similar but not identical phosphatidylinositol kinase homologues in yeast. Mol. Biol. Cell. 1994, 5, 105-118.
63. Sabers, C.J.; Martin, M.M.; Brunn, G.J.; Williams, J.M.; Dumont, F.J.; Wiederrecht, G.; Abraham, R.T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 1995, 270, 815-822.
64. Dames, S.A. A fast and simple method to prepare the FKBP-rapamycin binding domain of human target of rapamycin for NMR binding assays. Protein Expr. Purif. 2008, 59, 31-37.
65. Lorenz, M.C.; Heitman, J. TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin. J. Biol. Chem. 1995, 270, 27531-27537.
66. Choi, J.; Chen, J.; Schreiber, S.L.; Clardy, J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 1996, 273, 239-242.
67. Joo, E.K.; Broxmeyer, H.E.; Kwon, H.J.; Kang, H.B.; Kim, J.S.; Lim, J.S.; Choe, Y.K.; Choe, I.S.; Myung, P.K.; Lee, Y. Enhancement of cell survival by stromal cell-derived factor-1/CXCL12 involves activation of CREB and induction of Mcl-1 and c-Fos in factor-dependent human cell line MO7e. Stem Cells Dev. 2004, 13, 563-570.
68. Lawrence, J.C.; Lin, T.A.; McMahon, L.P.; Choi, K.M. Modulation of the protein kinase activity of mTOR. Curr. Top. Microbiol. Immunol. 2004, 279, 199-213.
69. McMahon, L.P.; Yue, W.; Santen, R.J.; Lawrence, J.C., Jr. Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex. Mol. Endocrinol. 2005, 19, 175-183.
70. Lee, H.W.; Nam, K.O.; Park, S.J.; Kwon, B.S. 4-1BB enhances CD8+ T cell expansion by regulating cell cycle progression through changes in expression of cyclins D and E and cyclin-dependent kinase inhibitor p27kip1. Eur. J. Immunol. 2003, 33, 2133-2141.
71. Eto, I. Nutritional and chemopreventive anti-cancer agents up-regulate expression of p27Kip1, a cyclin-dependent kinase inhibitor, in mouse JB6 epidermal and human MCF7, MDA-MB-321 and AU565 breast cancer cells. Cancer Cell Int. 2006, 6, 20.